Objective: Malperfusion syndrome is a known predictor of poor outcomes in acute type B dissection. We describe our experience with revascularization in the acute setting. Methods: Patients undergoing intervention for ischemia complicated acute type B dissection between November 1999 and March 2011 were reviewed. Details of presenting condition, surgical intervention, and postoperative course were collected. Descriptive and inferential statistical analyses included survival and freedom from reintervention using Cox proportional hazards models. Results: A total of 61 patients were identified with malperfusion in at least one territory, including spinal cord 7/61 (12%), mesenteric 37/61 (61%), renal 45/61 (73%), and lower extremity 38/61 (62%). Thoracic stent grafts were placed in all patients, and 41% of patients required adjunctive branch vessel stenting. After intervention, resolution of the ischemia was reported in 57/61 (93%) of patients. The 30-day/in-hospital mortality was 21.3%. The 6-month, 1-year, and 5-year survival was 75% (95% CI, 65%-87%), 71% (95% CI, 61%-84%), and 56% (95% CI, 43%-74%), respectively. The 6month, 1-year, and 5-year freedom from reintervention was 84% (95% CI, 75%-95%), 76% (95% CI, 65%-90%), and 42% (95% CI, 24%-76%), respectively. Territory of ischemia was not independently associated with mortality, but placement of a stent graft proximal to the subclavian artery was associated with poor outcome hazard ratio 2.91 (95% CI, 1.09-8.11; P [ .034). Conclusions: Malperfusion in any territory at the time of presentation in patients with type B dissections can be treated with endovascular intervention with acceptable outcomes. Opposed to branch vessel intervention alone, increased aortic intervention with regard to proximal coverage may signify more serious disease is associated with worse outcome. (J Vasc Surg 2013;57:1283-90.) 
Ischemia caused by acute type B aortic dissection (ABAD) is a life-threatening medical emergency and occurs in approximately 15% to 42% of all ABAD patients. [1] [2] [3] Malperfusion caused by either a dynamic or static obstruction to the renal, mesenteric, spinal, or iliac arteries demands surgical intervention if the end organs are threatened. In cases where the organs are not threatened, and if there is no concern for acute aneurysm degeneration and rupture, medical therapy with aggressive antihypertensive and antiimpulse therapy are the mainstay therapies. 4 Two mechanisms have been accepted as the primary causes of ischemia following aortic dissection: (1) true lumen collapse in either a complete or transient manner and (2) extension of the dissection into visceral arteries causing branch vessel obstruction. 5 Failure to treat such malperfusion syndromes caused by complicated ABAD (cABAD) results in a >50% chance of death for affected patients. 1, 5 Several emergency surgical options exist to treat cABAD with open surgical aortic graft replacement and thoracic endovascular aortic repair (TEVAR), being the two main treatment options, whereas others have advocated fenestration. 6 Open surgical repair in these emergent cases has been associated with high morbidity and mortality. 1, 7 Since Dake first reported on the use of TEVAR for aortic dissection, 5 it has become accepted as an effective treatment for ABAD. 3, 5, [7] [8] [9] [10] [11] [12] [13] This procedure seeks to seal the entry tear, stent open the true lumen, and if possible, completely occlude the false lumen in a proximal to distal fashion. A growing body of knowledge has advocated TEVAR as the preferred treatment method for emergency ABAD treatment, and accordingly, open surgical correction of malperfusion is now rarely performed. 7, [9] [10] [11] [12] Data concerning the outcomes of TEVAR for ABAD complicated by ischemia (icABAD) are limited to small subsets of most study populations or by short-term follow-up. 12 This study aimed to assess overall survival and effectiveness of patients who received TEVAR for icABAD, with specific attention to those patients suffering from visceral malperfusion METHODS Patient selection. A retrospective chart review assessed all patients who had malperfusion resulting from Stanford type B aortic dissection. All patients who fit this criterion and presented with icABAD to one or more aortic branch vessels between November 1999 and March 2011 were screened for inclusion. Study data were collected from medical records and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Cleveland Clinic. 14 Information on 87 clinical variables was recorded concerning patient demographics and comorbidities, dissection extent, operative variables, aortic branch vessel involvement, and outcome measures.
Acute type B dissection was defined as a spontaneous, nontraumatic dissection involving the descending aorta that was diagnosed within 14 days of onset of symptoms. 15 Diagnosis of ABAD was based on the preoperative computerized axial tomography (CAT) scan. In general, the diagnosis of malperfusion in the context of ABAD was based on the patient's presenting symptoms in addition to computerized tomography confirmation and intraoperative visualization of obstruction to any aortic branch vessels. The categorization of presenting symptoms has been described by White et al 7 and includes (1) visceral hypoperfusion (acute abdomen, greater-than-expected abdominal pain based on physical examination findings, lactic acidosis, or requirement for bowel resection); (2) renal hypoperfusion (oliguria/anuria with rising blood creatinine and blood urea nitrogen levels); (3) lower extremity hypoperfusion (abnormal pulse examination associated with ischemic rest pain, off-pallor, paresthesia, or paralysis); and (4) spinal cord hypoperfusion (altered motor function in unilateral or bilateral lower extremities attributed to central nervous system dysfunction). All patients in extremis were offered repair or had a repair attempt made depending on admitted condition.
Exclusion criteria included type A dissection, open aortic graft replacement, traumatic dissection, and treatment for dissection at an outside hospital prior to transfer. Sixty-one patients were identified for inclusion based on these criteria. All patients underwent TEVAR. Subsequent to the primary analysis, three additional patients were identified who had only branch vessel stenting alone in the face of acute type B dissection and were excluded from initial analysis. Inclusion of these patients did not change the outcome of the study.
Variable definitions. All variables were reported based on standards established by the Society of Vascular Surgery Ad Hoc Committee on Reporting Standards for TEVAR. 16 All dissections included in this study were spontaneous with or without connective tissue disorders. Blood pressure control was gathered from preoperative in-office visits. Hypertension was determined from prior medical records. Tight blood pressure control was defined as constant management of systolic blood pressure #130. Uncontrolled hypertension was defined as two or more incidences of systolic blood pressure >130 during clinical visits or based on the attending physician's report. Pulmonary complication was defined as an inability to be weaned from a ventilator >24 hours postoperatively. Aortic diameter was measured perpendicular to the minor axis at the widest point recorded. Time to treatment represents the difference between procedure start time and time of admission. Endovascular procedure. The procedure generally involved three-vessel access, with open surgical right common femoral artery exposure, and left common femoral and left brachial percutaneous access. This approach was preferred because the wire and catheter provide graft placement landmarks for tears adjacent to the subclavian artery. In most cases, intravascular ultrasound was used in conjunction with conventional angiography to assist and confirm access was in the true lumen. Entry tear identification was attempted using intravascular ultrasound, but rapid restoration of perfusion was the primary goal. The aim of the thoracic stent graft placement was to seal the entry tear and expand the true lumen. The length of vessel treated was at the discretion of the surgeon, with above goals taken into consideration. No bare-metal components were implanted. Adjunctive branch vessel stenting was done to assist their true lumen expansion in the face of compromised flow because of extension of the flap into the vessel.
Statistical methods. De-identified data were imported from REDCap to SAS (SAS Institute, Cary, NC). Summaries of the entire cohort were created using medians and ranges for continuous measures and frequencies and percentages for categorical measures. This was done to identify any out-of-range values. Kaplan-Meier estimates of survival and freedom from reintervention were calculated along with 95% confidence intervals (CIs). Cox proportional hazard regression models were also fit, and hazard ratios from these models were used to estimate the risk of death or reintervention. Analyses were performed using SAS software (v. 9.2; SAS Institute). Table I . The presenting symptoms of ischemia were a prerequisite for study inclusion and were present in at least one vascular bed for all 61 patients. Fifty-four of the 61 patients (88.5%) analyzed had visceral ischemia (renal or mesenteric). Forty-three (70.5%) patients had more than or equal to two affected vascular beds, whereas 16 (26.2%) had more than or equal to three affected vascular beds. Ischemia was categorized by vascular bed affected and analyzed for survival estimates.
RESULTS

Patient demographics. Patient demographics are listed in
The 30-day/in-hospital mortality rate was 21.3% (13 patients). Intraoperative angiography showed ischemia resolution in 57 patients (93.4%). Two patients with unresolved restoration of flow (50%) died 1 day postoperatively because of unresolved mesenteric ischemia causing bowel death, whereas the other two were successfully discharged and were alive at the conclusion of this study. Cumulative survival at 6 months, 1, 3, and 5 years was 75% (95% CI, 65%-87%), 71% (95% CI, 61%-84%), 60% (95% CI, 47%-76%), and 56% (95% CI, 43%-74%), respectively (Fig 1) . Univariable factors associated with survival for demographics are listed in Table I . Men (hazard ratio [HR], 0.42; 95% CI, 0.18-0.96; P ¼ .04) and nonsmoking status (HR, 0.31; 95% CI, 0.10-0.99; P ¼ .047), were associated with improved survival, while acute and chronic renal failure (HR, 2.30; 95% CI, 0.90-5.88; P ¼ .083) trended toward decreased survival. Surprisingly, hypertension (HR, 0.35; 95% CI, 0.10-1.20; P ¼ .096) trended toward increased survival at all time points, but both renal failure and hypertension were not statistically significant (.05 < P < .10) for their respective associations with survival. It is worth noting that seven of nine patients who underwent TEVAR for icABAD with preoperative renal issues were dialysis dependent for the remainder of their follow-up period and four of these seven died #30 days.
Univariate analyses to determine if survival was associated with preoperative ischemic factors were performed (Table I) . No one type of ischemia was associated with decreased survival: spinal (HR, 2.13; 95% CI, 0.71-6.37; P ¼ .17), lower extremity (HR, 0.54; 95% CI, 0.23-1.25; P ¼ .15), mesenteric (HR, 1.82; 95% CI, 0.71-4.65; P ¼ .21), and renal (HR, 1.64; 95% CI, 0.56-4.87; P ¼ .37). When compared with patients suffering lower extremity ischemia alone, patients suffering visceral ischemia showed no significant differences in cumulative survival at 6 months or 1, 3, and 5 years (Fig 1) . There appeared to be a trend associating visceral ischemia with decreased long-term survival, but the associated P value was .21 rendering this finding insignificant.
Operative variables. Comparative data based on surgical demographic factors are presented in Table I . Median time to treatment was 60.3 6 97.4 hours. Because of the large SD, patients were grouped depending on whether they had received treatment within 24 hours or beyond 24 hours. Treatment time >24 hours (HR, 0.85; 95% CI, 0.36-2.00; P ¼ .72) and stent type (Zenith stent (Cook Medical, Bloomington, Ind) (HR, 1.32; 95% CI, 0.54-3.24; P ¼ .55) were not associated with diminished survival at 12, 36, or 60 months. No length of the stent graft was bare metal, as Zenith stents used between 1999 and 2004 were constructed intraoperatively. The proximal landing zone in reference to the left subclavian artery (LSA) was distal for 24 patients (39.3%), partially occluding in 10 patients (16.4%), and proximal in 27 patients (44.3%). Partial or complete coverage of the LSA was negatively associated with survival (HR, 2.97; 95% CI, 1.09-8.11; P ¼ .034). Although achieving at least 2 cm of proximal seal was not feasible in this emergent patient population, all efforts to maximize landing zone proximal to the primary entry tear were taken.
Branch vessel stenting was carried out in 25 patients (41%). The celiac and superior mesenteric arteries had bare metal stents deployed in one (1.6%) and six (9.8%) patients, respectively. Seventeen renal arteries were stented in 13 patients (21.3%). Iliac artery stenting was performed 19 times in 13 patients (21.3%). One patient had the LSA stented, and three patients (4.9%) had the left common carotid stented. These stents acted as chimneys when aortic grafts jumped proximally upon deployment. Branch vessel stenting (HR, 0.92; 95% CI, 0.39-2.15; P ¼ .84) was not associated with survival.
Preoperative false lumen status was also assessed. Upon admission, 46 patients (75.4%) had a patent false lumen, whereas 15 (24.6%) had either partial or complete thrombosis of the false lumen. This variable had no association with survival (HR, 1.00; P ¼ .99). Primary intimal entry tear was successfully occluded in 60 patients (98.4%). One patient suffered cardiac arrest intraoperatively following deployment of a stent graft with a small type IA endoleak. Although the patient was resuscitated, the endoleak was not repaired, as the patient succumbed to severe metabolic acidosis secondary to bowel infarction within 12 hours of the procedure.
Postoperative false lumen status was recorded at the last follow-up date for each patient. Mean follow-up time was 37.1 6 30.4 months. Eight patients (13.1%) had partial thrombosis of the false lumen following TEVAR, whereas eight (13.1%) achieved complete thrombosis. Twenty-five patients (40.9%) had complete thrombosis of the false lumen along the length of the stent graft but had a distal reentry tear that gave rise to a distal, patent false lumen. Because of either early mortality or lack of follow-up imaging studies, 20 patients (32.7%) were not assessed for postoperative false lumen status.
Complications. Table II outlines complications following TEVAR for icABAD. For the entire cohort, the median postoperative creatinine level was 2.50 6 0.72 mg/dL. Three patients (4.9%) suffered a stroke postoperatively. Two of these patients died within 3 weeks of their TEVAR procedures, whereas the third died within 3 months.
Late aortic events anytime during follow-up were prevalent in this complicated group with 25 patients (41%) experiencing at least one aortic-related complication. Novel aneurysm development occurred in seven patients (11.5%), with five of these patients requiring reintervention (71.4%). Retrograde dissection occurred in two patients (6.6%) with one requiring open surgical aortic graft repair of the ascending aorta. The second patient suffered retrograde dissection with concurrent multiple organ failure. His critical condition precluded ascending aortic graft replacement and he subsequently died 17 days postoperatively. Endoleaks were observed in 12 patients during follow-up. False lumen status at the time of reported endoleaks was recorded. Of those suffering type I endoleaks, three were not assessed because of early mortality, three had partial false lumen thrombosis, and one had a patent false lumen because of the endoleak. All four of the seven (57.1%) affected by type I endoleak who survived the initial dissection underwent a reintervention operation. All type II endoleak patients had partial thrombosis as a result of their endoleaks, and three of four affected by type II endoleak had reinterventions performed. The single patient who had a type III endoleak suffered from Ehlers-Danlos syndrome and presented with mesenteric ischemia. The graft was placed emergently, but because of the friability of this patient's aorta, dilation occurred requiring open graft replacement. No further reinterventions were required during 3-year follow-up. Kaplan-Meier estimates for freedom from reintervention for the entire cohort were calculated and are presented in Fig 2. Percentage estimates for 6, 12, 36, and 60 months were 84% (95% CI, 75%-95%), 76% (95% CI, 65%-90%), 68% (95% CI, 53%-86%), and 42% (95% CI, 24%-76%), respectively.
Univariable analysis was carried out for patient demographic and surgical demographic factors for freedom from reintervention (Table III) . Those who quit smoking preoperatively had a significant increase in freedom from reintervention (HR, 0.23; 95% CI, 0.07-0.74; P ¼ .014). In addition, nonsmokers had a strong trend toward avoidance of reintervention compared with smokers but did not reach statistical significance (HR, 0.23; 95% CI, 0.05-1.05; P ¼ .058). Spinal cord ischemia was identified as a significant risk factor for reintervention (HR, 5.39; 95% CI, 1.35-21.6; P ¼ .017). All patients who experienced ischemia to this vascular bed required reintervention within 1-year post-TEVAR. Branch vessel stenting was also negatively associated with freedom from reintervention (HR, 4.33; 95% CI, 1.39-13.5; P ¼ .012). When comparing those with lower extremity ischemia alone with those with visceral ischemic involvement, no significant difference was found for freedom from reintervention (HR, 0.97; 95% CI, 0.27-3.47; P ¼ .97).
DISCUSSION
The first report of treating ischemia-complicated acute type B aortic dissection using endovascular stent grafts was in 1999 by Dake et al. 5 Since this initial report, many studies have postulated that TEVAR for icABAD may be superior to open surgical aortic graft replacement in terms of increased short-term and overall survival, but few have separated ischemia cABAD patients from the larger pool of patients with cABAD. Therefore, the purpose of this study was to determine survival and freedom from reintervention outcomes for this specific cohort.
Specific variables were predictive for survival in our cohort. Women had a significant association with decreased 30-day survival. Nienaber et al have examined this genderrelated difference in survival previously. 17 They reported that women had a significantly decreased survival rate because of later presentation and older age. Nienaber et al also cited a trend toward greater time to treatment as being a likely negative factor. Nonsmoking status was also associated with increased survival in our cohort. This is not surprising, as the toxic effects of tobacco smoking on the vasculature are well established. 18 Paradoxically, hypertensive patients trended toward having an increased cumulative survival. It is possible that high blood pressure could be protective after the onset of ischemia to deliver intermittent flow to malperfused vascular beds until anti-impulse therapy was started. Preoperative renal insufficiency and failure, whether acute or chronic, also trended toward decreased survival. Acute renal failure has been shown to significantly increase early mortality for in-hospital patients and has also been associated with respiratory failure. 19 Along with renal ischemia that was concurrent in eight of the nine patients with preoperative renal problems, there was a large increase in early mortality risk imparted by the combination of these disorders.
Left subclavian artery occlusion by the TEVAR graft was an independent predictor of decreased survival in this cohort. Recent research has shown trends in higher rates of cerebrovascular accident in patients with LSA occlusion, and two of our three stroke patients had a proximal landing zone proximal to the LSA. 20 These findings are substantiated by the Study of Thoracic Aortic Type B Dissection Using Endoluminal Repair (STABLE) trial in which all patients who suffered strokes had LSA coverage. 21 The need to cover the LSA with a thoracic stent graft to occlude the primary entry tear indicates the severity of aortic disease present, which could also contribute to the early mortality of the patient.
Our in-hospital/30-day mortality rate of 21.3% was higher compared with results described in multiple contemporary studies examining TEVAR for malperfusion caused by type B dissection. 8, 9, 11, 22 Specifically, Conrad et al reported 12% 30-day mortality in a 33-patient cohort, 23 10.7% in a 28 patient cohort, 24 and White reported a conglomerate study mortality of 10.8%. 7 The differences in survival may be the patient acuity, as all of the patients in our study presented with severe end-organ ischemia and emergent operative indications. In 36 patients (59.0%), these indications prompted emergent TEVAR less than 24 hours after admission with three (4.9%) receiving dialysis in the operating room. Reperfusion was successful in 57 patients (93.4%), which suggests that ischemic damage in many patients in the 30-day mortality cohort had advanced beyond repair by the time treatment could be initiated. Of the 13 patients who died within 30 days of treatment, seven succumbed to either multiple organ failure or reperfusion injury because of ischemia. Malperfusion as a result of ABAD is known to be a risk factor for high morbidity and mortality in the already-high-risk ABAD patient population, but treatment with open surgery has been reported to have a 30-day mortality ranging from 30.8% to 88% for patients presenting with mesenteric ischemia. 22, 25 Although we did not find any significant difference in survival or freedom from reintervention between those treated before or after 24 hours, delays in treating an ischemic condition undoubtedly cause irreversible damage.
Actuarial survival at 1, 3, and 5 years was 71%, 60%, and 56%, respectively. The 1-year survival rate of the present study was within the range of contemporary studies done on cABAD patients with very few studies having performed actuarial analysis to 5 years with a cABAD cohort. 22 Verhoye et al reported no late deaths in a cohort of 16 patients at 5 years. Compared with our cohort however, only 50% suffered malperfused branch arteries in their study. 9 Necrosis attributable to ischemia was the cause of death in seven of 13 patients (54%) in our 30-day mortality cohort, which underlines the limitations of any treatment method for icABAD. Delays in diagnosis or transfer to a hospital equipped to treat these patients can be the difference between life and death. 27 Because most patients in the study were transferred from an outside hospital, determining diagnosis or treatment delay-related mortality was not within the scope of this study.
Because of the small number of events despite compiling 12 years of icABAD patients, visceral ischemia cases were pooled and compared with cases with lower extremity ischemia only. Survival in patients with visceral ischemia was not significantly associated with decreased survival vs patients suffering lower extremity ischemia alone, although a trend toward decreased survival was observed. Previous studies have identified visceral ischemia as an independent predictor of perioperative mortality in open surgical patients, 26 but no such delineation between visceral and lower extremity ischemia has been reported with multiple studies identifying malperfusion of any vascular bed as an independent mortality predictor. 1, 22, 27 We, therefore, recommend that any of the aforementioned signs of malperfusion following blood pressure optimization should be aggressively treated.
Identifying factors imparting freedom from reintervention was the other major objective of this study. Nonsmokers had a significant decrease in the need for reintervention. Increased healing times, hypercoagulability imparted by cigarette smoke, and a plethora of other effects that cigarette smoke has on vascular disease are doubtlessly attributable to this finding. 18 Spinal cord ischemia at presentation was associated with decreased freedom from reintervention. One theory is that surgeons are hesitant to extensively cover zone IV of the descending aorta because of the risk of cutting off collateral flow to the cord. This shortened coverage could prevent complete re-expansion of the true lumen, leaving obstruction of aortic branch vessels as a possibility. In addition, spinal cord ischemia would be a reason to choose a proximal landing zone distal to the left subclavian to avoid reducing collateral flow from the LSA to the spinal column. We recommend treating the primary entry tear, and angiographic evidence of perfusion to malperfused vascular beds should be obtained. Care should always be taken to avoid coverage of T8-L2, as stent graft coverage of this area has been associated with spinal cord malperfusion. 28 Gore stent as reference value (HR, 1.00).
JOURNAL OF VASCULAR SURGERY
However, in the setting of ischemia, it is more important to provide adequate flow. Also, to avoid late aortic events, we are now more inclined to cover more distal aorta if it is affected by the dissection. Adjunctive use of a spinal drain set to 10 cm water pressure as well as maintenance of a mean arterial pressure $70 mm Hg can both be effective in restoring and maintaining flow to the spinal cord. Not surprising, branch vessel stenting was also negatively associated with freedom from reintervention. Static obstruction of aortic branch vessels can persist despite depressurization of the false lumen and elimination of dynamic obstruction because of extension of the false lumen into branch vessel ostia. 8 The need to place branch vessel stents indicates a more severe dissection pathology that is not amenable to TEVAR alone. Continued signs of malperfusion relating to the lack of adequate reperfusion as well as the inherent complexity with placing branching stents into the diseased true lumen may require a second operation to extend stenting into branch vessels or extend the thoracic endograft to eliminate distal perfusion of the false lumen via reentry tears.
This study is not without limitations. This is a nonrandomized, single-center, retrospective study that cannot draw firm, evidence-based conclusions about TEVAR vs other therapies. In addition, exact entry site determination could not be made for all patients, which precluded proximal entry tear site in reference to the LSA from being analyzed as a predictor of survival. The length of aorta covered by implanted grafts was also not measured in this cohort, and both of these variables will be topics for a future study. Finally, whereas our study encompasses the major cohort of symptomatic type B dissections, despite 12 years' experience treating icABAD patients with TEVAR, our sample size of 61 patients was too small for meaningful multivariate analyses to be performed. However, this is to our knowledge, one of the largest single-center cohorts of icABAD patients treated using TEVAR and stent grafting reported in the literature.
In conclusion, TEVAR is an effective and safe mode for treating icABAD. A review of IRAD data specifically targeting malperfusion may be beneficial in elucidating more predictors of morbidity, mortality, and freedom from reintervention. Were most of these patients who came in with renal ischemia as well, or was this secondary to the procedure?
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Dr Timur P. Sarac (Cleveland, Ohio). Most of the patients who came in with a dissection flap obstructing the renal arteries with acute renal failure. All the patients in this cohort received a stent graft for it. We had three patients who we subsequently reanalyzed and went back and looked at all of our visceral stenting, and only three patients which were not included in this actually had stenting of the visceral vessels that we did not put in a thoracic stent graft. So, our bias is to treat the dissections with the stent graft and exclude the entry tear and expand the true lumen as much as possible. Adjunctive stenting of the branch vessel was necessary in 25% of the patients.
Dr Firas Mussa (New York, NY ). Could you predict why did those who had left subclavian coverage ended up with a worse outcome?
Dr Sarac. There is one patient in this series who we covered the subclavian artery who had a retrograde dissection who expired. There is no way for me to tell you exactly what the reason is other than to say that it really is an indication of the extent of the disease, which acts as a metric for the patients overall condition as these patients have very diseased aortas and branch vessels.
Dr Richard Cambria (Boston, Mass). Tim, I wanted to ask a question about how you defined your patient population. I agree with your conclusion that 20% mortality at 30 days is acceptable in these patients. When we first presented such a series 25 years ago at this meeting, the mortality for visceral ischemia complicating dissection was 80%. But my question relates to how you define visceral ischemia. Were these radiographic definitions? Were they clinically manifest visceral ischemia? And what did the patients die from?
At 20%, the 30-day mortality is a little higher than the Society of Vascular Surgery Outcomes Committee objective performance criteria paper, which had 10% 30-day mortality. So your thoughts on how the patients might differ.
Dr Sarac. All of the patients all presented with severe symptoms of end organ-ischemia. For example, for renal failure, they were oliguric and had rising creatinine, and for visceral involvement, their lactates were very high, and they had abdominal pain. So, all these patients truly had emergent operative indications.
If you look at the number of patients in this group that were treated within 24 hours of presentation, it was more than one-half of them. Three of the patients actually underwent dialysis in the operating room. I think that may have been the difference in patient population between the two.
Looking at the International Registry of Acute Aortic Dissections (IRAD) registry, of which there are several excellent reports out, even in the past 4 months, the cohort of mesenteric patients and the mortality rate can be as high as 64% in one subsequent post hoc analysis. Dr Sarac. The overall spinal cord ischemia rate was 11.3%. If the time will allow during the patient's clinical presentation, we will get a spinal drain in. That happened in less than one-half of these patients. Postop all the patients are monitored closely, and we tend to keep the mean arterial pressure much higher than we normally would. And this is a high complication rate of 10% or 11% for spinal cord ischemia. One-half of those were paraparesis that recovered and half of them went on to infarction.
Dr John Ricotta (Washington, DC). Tim, as I saw it, you had a very high reintervention rate, which certainly has been the experience of a lot of people including our own experience. How do you follow these patients?
One of the Achilles' heels of this whole problem is that the false lumen does not thrombose in most of the patients. They still have a diseased aorta, and they do not necessarily get very good follow-up either for the management of their hypertension or for late complications, which occurred in about one-half of your patients. Could you comment about what your protocol is and how you think we could improve our care paths in that regard.
Dr Sarac. All the patients get a computerized axial tomography scan before they leave the intensive care unit, particularly the ones who have a spinal drain in. They are all seen again at 1 month and then 6 months, every 6 months for the first couple of years.
The point of hypertension control is a big deal. And the reason I say that is that in most of the patients, as with most of the tertiary and quaternary places that are doing thoracic endovascular aortic repair for dissections, it is difficult to manage their hypertension as surgeons and getting their primary care doctors involved is important. Certainly, the patients in our institute initially get admitted to the cardiology unit, and they do a great job of getting the hypertension under control. But postoperatively, that is a big deal and we have a big concern for following these patients and maybe we ought to be doing more for that.
One of the things that we have adopted, and I think more anecdotal evidence, but Dan and I were talking about the length and what length of aorta we cover. And I think our bias now is to cover as much of this as we can. I am interested to see about the long-term results of the recently reported Petticoat trial, if that will make a difference when we use a bare-metal stent in the distal aorta area. But, we do tend to cover as far as we can all the way down to the celiac artery.
